A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet
Launched by BORYUNG PHARMACEUTICAL CO., LTD · Apr 29, 2016
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy subject, aged 19- 50 years
- Exclusion Criteria:
- • History of clinically significant and active disease
- • History of gastrointestinal disease
- • History of clinically significant hypersensitivity to study drug, any other drug
- • Laboratory test serum AST or ALT \> 1.25 times of upper normal range serum total bilirubin \> 1.5 times of upper normal range eGFR \< 60 ml/min/1.73m² serological test(HBsAg, HCV Ab, HIV Ag/Ab, Syphilis reagin) positive
- • Hypotension or hypertension
- • Pregnant or nursing women
- • Participation in any other study within 90 days
About Boryung Pharmaceutical Co., Ltd
Boryung Pharmaceutical Co., Ltd. is a leading South Korean biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutic solutions. Established with a commitment to advancing healthcare, Boryung focuses on various therapeutic areas, including oncology, cardiology, and infectious diseases. The company leverages cutting-edge technologies and robust clinical trial methodologies to bring new medications to market, enhancing patient outcomes globally. With a strong emphasis on quality and compliance, Boryung Pharmaceutical continues to expand its footprint in the global pharmaceutical landscape through strategic collaborations and a dedication to scientific excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials